Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Everly

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
Clinical Transplants|August 28, 2009
Detailed examination of HLA antibody development on renal allograft failure and functionLan Zhu, Po-Chang Lee, Matthew J Everly, et al.
Clinical Transplants|July 5, 2012
Understanding the significance of low-level preformed donor-specific anti-HLA antibodies in renal transplant patientsPingping Wu, Matthew J Everly, Juan Jin, et al.
The Annals of Pharmacotherapy|October 18, 2007
Posttransplant lymphoproliferative disorderMatthew J Everly, Roy D Bloom, Donald E Tsai, et al.
Clinical Transplants|June 8, 2010
Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case reportJignesh K Patel, Matthew J Everly, Michelle Kittleson, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 25, 2019
Trajectories of health-related quality of life among renal transplant patients associated with graft failure and symptom distress: Analysis of the BENEFIT and BENEFIT-EXT trialsIntan Purnajo, Jennifer L Beaumont, Martin Polinsky, et al.
Transplantation|May 18, 2012
Using donor-specific antibodies to monitor the need for immunosuppressionJunichi Hoshino, Hugo Kaneku, Matthew J Everly, et al.
Transplantation|November 3, 2010
Protective immunity remains intact after antibody removal by means of proteasome inhibitionMatthew J Everly, Paul I Terasaki, Judy Hopfield, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 17, 2018
Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohortsMatthew J Everly, Mustimbo Roberts, Robert Townsend, et al.
Clinical Transplants|June 8, 2010
Removal of physiologic corticosteroid doses results in HLA antibody appearance and allograft dysfunction in patients transplanted under a clonal deletion protocolMatthew J Everly, Fay Jahr, Hugo Kaneku, et al.
Clinical Biochemistry|June 4, 2013
Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantationPingping Wu, Juan Jin, Matthew J Everly, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
Clinical Transplants|August 28, 2009
Detailed examination of HLA antibody development on renal allograft failure and functionLan Zhu, Po-Chang Lee, Matthew J Everly, et al.
Clinical Transplants|July 5, 2012
Understanding the significance of low-level preformed donor-specific anti-HLA antibodies in renal transplant patientsPingping Wu, Matthew J Everly, Juan Jin, et al.
The Annals of Pharmacotherapy|October 18, 2007
Posttransplant lymphoproliferative disorderMatthew J Everly, Roy D Bloom, Donald E Tsai, et al.
Clinical Transplants|June 8, 2010
Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case reportJignesh K Patel, Matthew J Everly, Michelle Kittleson, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 25, 2019
Trajectories of health-related quality of life among renal transplant patients associated with graft failure and symptom distress: Analysis of the BENEFIT and BENEFIT-EXT trialsIntan Purnajo, Jennifer L Beaumont, Martin Polinsky, et al.
Transplantation|May 18, 2012
Using donor-specific antibodies to monitor the need for immunosuppressionJunichi Hoshino, Hugo Kaneku, Matthew J Everly, et al.
Transplantation|November 3, 2010
Protective immunity remains intact after antibody removal by means of proteasome inhibitionMatthew J Everly, Paul I Terasaki, Judy Hopfield, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 17, 2018
Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohortsMatthew J Everly, Mustimbo Roberts, Robert Townsend, et al.
Clinical Transplants|June 8, 2010
Removal of physiologic corticosteroid doses results in HLA antibody appearance and allograft dysfunction in patients transplanted under a clonal deletion protocolMatthew J Everly, Fay Jahr, Hugo Kaneku, et al.
Clinical Biochemistry|June 4, 2013
Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantationPingping Wu, Juan Jin, Matthew J Everly, et al.
Pageof 7